keyword
MENU ▼
Read by QxMD icon Read
search

Apheresis stem cells

keyword
https://www.readbyqxmd.com/read/28631842/uk-consensus-statement-on-the-use-of-plerixafor-to-facilitate-autologous-peripheral-blood-stem-cell-collection-to-support-high-dose-chemoradiotherapy-for-patients-with-malignancy
#1
Kenneth W Douglas, Maria Gilleece, Patrick Hayden, Hannah Hunter, Peter R E Johnson, Charlotte Kallmeyer, Ram K Malladi, Shankara Paneesha, Rachel Pawson, Michael Quinn, Kavita Raj, Deborah Richardson, Stephen Robinson, Nigel Russell, John Snowden, Anna Sureda, Eleni Tholouli, Kirsty Thomson, Mike Watts, Keith M Wilson
Plerixafor is a CXC chemokine receptor (CXCR4) antagonist that mobilizes stem cells in the peripheral blood. It is indicated (in combination with granulocyte-colony stimulating factor [G-CSF]) to enhance the harvest of adequate quantities of cluster differentiation (CD) 34+ cells for autologous transplantation in patients with lymphoma or multiple myeloma whose cells mobilize poorly. Strategies for use include delayed re-mobilization after a failed mobilization attempt with G-CSF, and rescue or pre-emptive mobilization in patients in whom mobilization with G-CSF is likely to fail...
June 20, 2017: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/28626370/donor-safety-in-haemapheresis-development-of-an-internet-based-registry-for-comprehensive-assessment-of-adverse-events-from-healthy-donors
#2
Hans-Gert Heuft, Eike Fischer, Tina Weingand, Thomas Burkhardt, Gerda Leitner, Hagen Baume, Jörg-Peter Schmidt, Andreas Buser, Gabriele Fauchald, Ute Reinicke Voigt, Behrouz Mansouri-Taleghani
BACKGROUND: Currently, there is an extensive but highly inconsistent body of literature regarding donor adverse events (AEs) in haemapheresis. As the reports diverge with respect to types and grading of AEs, apheresis procedures and machines, the range of haemapheresis-related AEs varies widely from about 0.03% to 6.6%. METHODS: The German Society for Transfusion Medicine and Immunohaematology (DGTI) formed a 'Haemapheresis Vigilance Working Party' (Arbeitsgemeinschaft Hämapheresevigilanz; AGHV) to create an on-line registry for comprehensive and comparable AE assessment with all available apheresis devices in all types of preparative haemapheresis: plasmapheresis (PLS), plateletpheresis (PLT), red blood cell apheresis, all kind of leukaphereses (autologous/allogeneic blood stem cell apheresis, granulocyte apheresis, lymphocyte/monocyte apheresis) and all possible types of multi-component apheresis...
June 2017: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/28596651/bacteremia-during-early-post-allogeneic-hematopoietic-stem-cell-transplantation-period-a-single-center-experience
#3
Amro Mohamed Sedky El-Ghammaz
Bacteremia is a significant complication of allogeneic hematopoietic stem cell transplantation (HSCT). We aimed to study bacteremia occurring during early post-transplant period at Bone Marrow Transplantation Unit of Ain Shams University regarding its risk factors and impact on survival. Patients performing allogeneic HSCT were followed up for occurrence of bacteremia. Survival status was assessed at 180 days post-transplant. Bacteremia occurred in 53.3 % of patients. On univariate analysis, CD34 +ve cell dose (P = 0...
June 2017: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/28580637/influence-of-plerixafor-on-the-mobilization-of-cd34-cell-subpopulations-and-lymphocyte-subtypes
#4
Nina Worel, Nelli Frank, Christian Frech, Gerhard Fritsch
BACKGROUND: Peripheral blood stem cells mobilized with granulocyte-colony-stimulating factor (G-CSF) with or without chemotherapy are routinely used for autologous hematopoietic cell transplantation. Plerixafor, a chemokine-receptor inhibitor, increases the amount of circulating CD34+ cells and improves harvest results. However, limited information is available regarding the composition of apheresis products with respect to CD34+ and lymphocyte subtypes collected after various mobilization regimens...
June 5, 2017: Transfusion
https://www.readbyqxmd.com/read/28556233/poor-peripheral-blood-stem-cell-mobilization-affects-long-term-outcomes-in-multiple-myeloma-patients-undergoing-autologous-stem-cell-transplantation
#5
Jan S Moreb, Michael Byrne, Ilicia Shugarman, Fei Zou, Sican Xiong, William S May, Maxim Norkin, John Hiemenz, Randall Brown, Christopher Cogle, John R Wingard, Jack W Hsu
BACKGROUND: Peripheral blood stem cell (PBSC) mobilization is routinely undertaken prior to autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). A number of studies have identified risk factors for poor PBSC mobilization, however, little data exists to correlate mobilization with disease-specific outcomes in this patient population. Prospective work in MM has demonstrated similar outcomes in a homogenous patient population. METHODS: In this single institution analysis, we retrospectively studied the impact of poor PBSC mobilization on progression free survival (PFS) and OS in MM patients undergoing PBSC mobilization...
May 29, 2017: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/28541555/effective-chemomobilization-with-etoposide-and-cytarabine-ec-regimen-in-lymphoma-patients-a-single-center-retrospective-observational-study
#6
Daisuke Koyama, Satoshi Nishiwaki, Yasuhiko Harada, Satomi Yamamoto, Shingo Kurahashi, Takumi Sugimoto, Toshihiro Iwasaki, Isamu Sugiura
Objective: Autologous stem cell transplantation is an important strategy for patients with relapsed or refractory lymphoma. Although various regimens for peripheral blood stem cell collection have been used, the optimal regimen has not yet been established. We aimed to evaluate the mobilization efficacy and safety of the regimen consisted of etoposide and cytarabine (EC regimen). Methods: We retrospectively analyzed the clinical data of 46 lymphoma patients who received peripheral blood stem cell mobilization with the EC regimen [etoposide (100 mg/m2/day, days 1-4) and cytarabine (100 mg/m2/day, days 1-4)] at Toyohashi municipal hospital from 2004 to 2013...
May 24, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28540851/from-xe-2100-to-xn-9000-from-sis-standard-to-gfhc-recommendations-for-slide-review-potential-impact-on-review-rate-and-turnaround-time
#7
Anne Tamigniau, Nicolas Bailly, Bernard Chatelain, François Mullier
In 2014, we moved from XE-2100 with Standard SIS rules to XN-9000 with GFHC recommendations for slide review. The aim of our study was to evaluate the potential impact of the new Sysmex(®) automation with implementation of GFHC rules on our review rate, turnaround time (TAT), workload and on CD34+ stem cells enumeration. We conducted a retrospective observational study from September 2013 through August 2014, in CHU Dinant Godinne UCL Namur. With the GFHC recommendations and the new Sysmex(®) automation, we significantly reduced our review rate by nearly 30% considering all units (35...
June 1, 2017: Annales de Biologie Clinique
https://www.readbyqxmd.com/read/28528807/comparison-of-amicus-and-cobe-spectra-for-allogenic-peripheral-blood-stem-cell-harvest-study-from-tertiary-care-centre-in-india
#8
Rasika Dhawan Setia, Satyam Arora, Anil Handoo, Tina Dadu, Dharma Choudhary, Sajeev Kumar Sharma, Gaurav Kharya, Vipin Khandelwal, Prerna Sachdeva, Divya Doval, Anamika Bakliwal, Meenu Kapoor, Shalu Bajaj, Virendra Bachchas, Praveen Singh
INTRODUCTION: Most common source of stem cell graft for both autologous and allogenic haematopoietic transplants are peripheral blood haematopoietic progenitor stem cells. Adequate collection of the CD34+ cells and safety of the allogenic donor during the leukapheresis are of prime importance to an apheresis physician. Our retrospective analysis is a comparison between of two platforms namely, COBE Spectra and Amicus, for CD34+ mononuclear cell collection. MATERIAL AND METHOD: The study included the data of GSCF (Granulocyte-Colony-Stimulating Factor) mobilized allogenic PBSC collections at our centre from January 2015 to June 2016...
April 24, 2017: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/28527129/efficacy-and-safety-of-plerixafor-for-the-mobilization-collection-of-peripheral-hematopoietic-stem-cells-for-autologous-transplantation-in-japanese-patients-with-multiple-myeloma
#9
Masaki Ri, Kosei Matsue, Kazutaka Sunami, Chihiro Shimazaki, Akio Hayashi, Yoshinori Sunaga, Toru Sasaki, Kenshi Suzuki
To evaluate the efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells (HSCs) for autologous transplantation in Japanese patients with multiple myeloma (MM). In a randomized study, patients received G-CSF (filgrastim, 400 µg/m(2)/day) for 4 days prior to the first dose of plerixafor. Starting on Day 4 evening and for up to 4 days, patients received either plerixafor (240 µg/kg/day) + G-CSF group (PG group) or G-CSF alone (G group). Daily apheresis started on Day 5 for up to 4 days, or until ≥6 × 10(6) CD34+ cells/kg were collected...
May 19, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/28526045/standardization-of-platelet-releasate-products-for-clinical-applications-in-cell-therapy-a-mathematical-approach
#10
Francesco Agostini, Jerry Polesel, Monica Battiston, Elisabetta Lombardi, Stefania Zanolin, Alessandro Da Ponte, Giuseppe Astori, Cristina Durante, Mario Mazzucato
BACKGROUND: Standardized animal-free components are required for manufacturing cell-based medicinal products. Human platelet concentrates are sources of growth factors for cell expansion but such products are characterized by undesired variability. Pooling together single-donor products improves consistency, but the minimal pool sample size was never determined. METHODS: Supernatant rich in growth factors (SRGF) derived from n = 44 single-donor platelet-apheresis was obtained by CaCl2 addition...
May 19, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28485072/therapeutic-plasma-exchange-in-children-one-center-s-experience
#11
Gerard Cortina, Violeta Ojinaga, Thomas Giner, Magdalena Riedl, Siegfried Waldegger, Alejandra Rosales, Raphaela Trojer, Johannes Hofer
BACKGROUND: Therapeutic plasma exchange (TPE) has evolved to an accepted therapy for selected indications. However, it is technically challenging in children. Moreover, data on safety and efficacy are mainly derived from adult series. The aim of this study was to review the procedure in the context of clinical indications, effectiveness, and safety. STUDY DESIGN AND METHODS: All TPE procedures performed at a tertiary care hospital during a 12-year period (2005-2016) were retrospectively evaluated...
May 9, 2017: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/28485020/pegylated-granulocyte-colony-stimulating-factor-versus-non-pegylated-granulocyte-colony-stimulating-factor-for-peripheral-blood-stem-cell-mobilization-a-systematic-review-and-meta-analysis
#12
Jew W Kuan, Anselm T Su, Chooi F Leong
Granulocyte-colony stimulating factor (G-CSF) mobilizes and increases the amount of hematopoietic stem cells in peripheral blood, enabling its harvest by few apheresis procedures. The pegylated G-CSF has longer half-life and is given once only, which is more comfortable for patients, whereas the non-pegylated requires multiple daily injection because of its short half-life. We summarized results of randomized trials comparing the efficacy and safety of pegylated and non-pegylated G-CSF for peripheral blood stem cell mobilization...
May 9, 2017: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/28469899/reducing-central-venous-catheter-use-in-peripheral-blood-stem-cell-donation-quality-improvement-report
#13
Samer Ghazi, Ahmed Alaskar, Mohsen Alzahrani, Moussab Damlaj, Khadega A Abuelgasim, Giamal Gmati, Mona Alshami, Salman Alshammary, Khaled Al-Surimi, Hind Salama, Ayman Alhejazi, Abdul-Rahman Jazieh
Peripheral blood stem cell (PBSC) collection from donors through apheresis has become the main source of stem cells for hematopoietic stem cell transplantation. This procedure requires a high blood flow venous access. A peripheral venous catheter (PVC), compared to a central venous catheter (CVC), is considered to provide safer venous access. However, initially at our institution, King Abdul-Aziz Medical City - Riyadh, a CVC was frequently used (72%). A quality improvement multidisciplinary team has been formed to conduct a systematic quality performance analysis to evaluate the current process of collecting donor PBSCs with the aim to reduce CVC use to less than the international benchmark (20%)...
2017: BMJ Quality Improvement Reports
https://www.readbyqxmd.com/read/28455878/impact-of-plerixafor-mozobil-on-hospital-efficiency-a-single-center-experience
#14
Nabih Azar, Maya Ouzegdouh, Sylvain Choquet, Véronique Leblond
Plerixafor (Mozobil) in combination with granulocyte colony-stimulating factor (G-CSF) has shown to increase mobilization of peripheral blood stem cells (PBSC) as compared to G-CSF alone in patients undergoing autologous stem cell transplantation (ASCT). However, up to 25% of patients treated with G-CSF alone still fail mobilization. Adding plerixafor to poor mobilizers allows to rescue these patients from mobilization failure and to reduce the number of apheresis sessions. The goal of this retrospective study was to capture the impact of plerixafor on treatment outcome and on apheresis department efficiency...
April 28, 2017: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/28445013/comparison-of-two-apheresis-systems-of-cobe-and-optia-for-autologous-peripheral-blood-stem-cell-collection
#15
Se Na Lee, Ji Yeon Sohn, Jung Hee Kong, Hyeon Seok Eom, Hyewon Lee, Sun Young Kong
Peripheral blood stem cell (PBSC) transplantation following myeloablative therapy is a mainstay of treatment for various types of malignancies. This study aimed to evaluate the differences between the Optia MNC and COBE Spectra MNC systems (Terumo BCT, Japan) according to apheresis procedures and the parameters of apheresis, products, and collection. The clinical data of 74 patients who underwent autologous PBSC collection from July 2012 to July 2015 were reviewed retrospectively. The patients comprised 48 (65%) men and 26 (35%) women with a median age of 56 yr (range, 23-66 yr)...
July 2017: Annals of Laboratory Medicine
https://www.readbyqxmd.com/read/28439700/filgrastim-alone-versus-pegylated-filgrastim-alone-for-autologous-peripheral-blood-stem-cells-mobilization-in-newly-diagnosed-multiple-myeloma-patients
#16
Barbara Skopec, Matevz Skerget, Darja Zontar, Vesna Zadnik, Samo Zver
BACKGROUND: Autologous hematopoietic stem cell transplantation (aHSCT) is the recommended standard upfront treatment for transplant eligible myeloma patients. Considering possible complications related to chemotherapy-cytokine mobilization, cytokine-alone mobilization is often used. We compared mobilization with filgrastim alone to pegfilgrastim alone in newly diagnosed myeloma patients after induction treatment with bortezomib and dexamethasone. The comparison was made between peripheral blood stem cell (PBSC) yields, number of apheresis, hematopoietic stem cell subsets, and time to neutrophil and platelet engraftment after aHSCT...
April 24, 2017: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/28417344/biotherapy-in-inflammatory-diseases-of-the-cns-current-knowledge-and-applications
#17
REVIEW
Nicolas Collongues, Laure Michel, Jérôme de Seze
Biotherapy represents an innovative therapeutic approach that includes immunotherapy (vaccines, apheresis, and antibodies); gene therapy; and stem cell transplants. Their development helps to cross the bridge from bench to bedside and brings new hope of a cure for severe diseases in different fields of medicine. In neurology, a growing range of applications is being developed for these medications. Valuable results are now available in the field of autoimmunity, neuro-oncology, paraneoplastic manifestations, and neurodegenerative disorders...
May 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/28411174/evaluation-of-hematopoietic-stem-cell-mobilization-rates-with-early-plerixafor-administration-time-for-adult-stem-cell-transplantation
#18
Jessica T Stover, J Ryan Shaw, Maragatha Kuchibhatla, Mitchell E Horwitz, Ashley M Engemann
The addition of plerixafor to high-dose colony stimulating growth factor has been shown to improve stem cell mobilization rates in autologous transplant patients with multiple myeloma and non-Hodgkin's lymphoma. This study evaluates the change in administration time of plerixafor to determine if cell mobilization rates are similar between the FDA approved administration time of 11 hours prior to apheresis and an earlier administration time of 16 hours prior to apheresis. Medical records of patient ≥ 18 years of age undergoing autologous stem cell transplantation requiring the use of plerixafor after at least four days of G-CSF therapy to complete stem cell mobilization from 1 January 2010 through 30 September 2014 were retrospectively reviewed...
April 11, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28392150/factual-reflections-and-recommendations-on-extracorporeal-photopheresis-in-pediatrics
#19
REVIEW
Irena Sniecinski, Jerard Seghatchian
One of the biggest challenges in evaluating available literature on extracorporeal photopheresis (ECP) practices in pediatric patients is the marked heterogeneity of approaches to the patient evaluation, procedural aspects and apheresis product analysis. These issues are most relevant in ECP management in children with graft versus host disease (GVHD) after hematopoietic stem cell transplantation. Extracorporeal photopheresis in pediatric patients is considered relatively safe with few adverse effects reported from retrospective or observational studies...
March 22, 2017: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/28370131/use-of-allogeneic-apheresis-stem-cell-products-as-an-interlaboratory-proficiency-challenge
#20
Laura Cooling, Kelly Roxbury, Sandra Hoffmann, Joan DeBusscher, Usha Kota, Steven Goldstein, Robertson Davenport
BACKGROUND: AABB Standards requires that laboratories participate in a proficiency test (PT) program for critical analytes. Institutions can purchase commercial PT materials; however, PT can also be performed through interlaboratory exchange. We investigated the utility of allogeneic hematopoietic progenitor cell apheresis (HPC-A) products as an interlaboratory PT challenge for total nucleated cell count (TNC) and CD34 assessment. STUDY DESIGN AND METHODS: Three-year retrospective and comparative review of unrelated allogeneic HPC-A products received by the University of Michigan between January 2011 and December 2013...
March 28, 2017: Transfusion
keyword
keyword
41980
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"